Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sturlimogene erparepvec + tivozanib
- Development stage
- Unknown
- Lead developer
- Replimune
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Oral
01
Overview
This combination therapy consists of sturlimogene erparepvec (RP2) and tivozanib. Sturlimogene erparepvec is an enhanced oncolytic herpes simplex virus type 1 (HSV-1) designed to selectively replicate in and lyse tumor cells. It is engineered to express a fusogenic protein (GALV-GP R-), human GM-CSF, and an anti-CTLA-4 antibody-like molecule to stimulate a potent systemic anti-tumor immune response. Tivozanib is a selective small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, thereby inhibiting angiogenesis and tumor growth. The combination is being evaluated by City of Hope Medical Center in Phase 2 clinical trials for patients with metastatic renal cell carcinoma (RCC) who have progressed after receiving immunotherapy with immune checkpoint inhibitors.
- Brand names
- Fotivda
- Other names
- RP2 + tivozanibsturlimogene erparepvec + tivozanib hydrochloride
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on sturlimogene erparepvec + tivozanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sturlimogene erparepvec + tivozanib.